To determine the influence of cardiac motion on measurements of left ventricular (LV) mass obtained with 64-slice computed tomography (CT) and to elucidate the prognostic value of LV mass on major adverse cardiac events (MACE) and all-cause mortality. Increased LV mass has been linked with MACE. Although Cardiac CT allows measurement of LV anatomy, it is susceptible to motion artefacts often requiring image acquisition during diastasis. There is a need to understand variability in LV mass measurements across phases of the cardiac cycle, and whether mid-diastolic measurements have prognostic value.
Introduction
Left ventricular (LV) hypertrophy is a strong predictor of cardiovascular (CV) morbidity. 1 Accurate measures of LV hypertrophy and LV mass can identify patients who are at risk of future major adverse cardiac events (MACE) 2 and can guide treatment of conditions associated with LV hypertrophy, such as hypertension to reduce target organ damage. 3, 4 LV mass has been routinely estimated with echocardiography by using end-diastolic measurements acquired in a single plane. 5 However, these estimates are limited by geometrical assumptions as well as technical limitations such as poor acoustic windows (due to obesity or pulmonary disease). 6 Accurate methods of measuring LV mass are desirable, especially when it can be obtained at no incremental cost.
Cardiac computed tomography (CT) is an imaging technique that permits the accurate visualization of the coronary arteries, left ventricle, right ventricle, and the myocardium. The Society of Cardiovascular Computed Tomography recommends measurements of the LV mass using Cardiac CT. 7 As a radiation reduction technique, Cardiac CT images are prospectively electrocardiogram (ECG)-triggered and typically acquired in mid-diastole, in order to minimize motion artefact. 8 Recently, Budoff et al. showed that LV mass measured in end-diastole and end-systole with CT had minimal (,5%) variability. 9 Whether or not this holds true at mid-diastole remains to be determined. The objectives of this study were (i) to determine the influence of cardiac motion on measurements of LV mass measures obtained with 64-slice CT and (ii) to understand the potential prognostic value of LV mass on MACE and all-cause mortality.
Methods

Study population
Patients who were referred to our centre and underwent a contrast-enhanced retrospective ECG-gated cardiac CT were prospectively enrolled to a site registry and were followed for all-cause mortality and MACE [non-fatal myocardial infarction (MI) and stroke]. 10 Patient follow-up was performed by trained research staff blinded to all clinical data. All events were confirmed with death records, hospital records, and/or correspondence with the patients' treating physicians. 10 The registry was retrospectively analysed to generate two matched cohorts with follow-up data. Patients with a history of coronary revascularization, heart transplantation, and congenital heart disease were excluded. Thus, a cohort comprising 83 patients with all-cause death, non-fatal MI, or stroke was identified. In addition, a matched (age, gender, BMI, and Morise risk score 11 ) event-free cohort of 83 patients was selected as control. The University of Ottawa Heart Institute Human Research Ethics Board approved the study.
Cardiac CT image acquisition
Prior to imaging, patients received medications to target a heart rate of ≤65 beats/min and nitroglycerin (0.8 mg) sublingually to dilate the coronary arteries. 12 -14 After a biphasic timing bolus, a triphasic intravenous contrast (Omnipaque 300 or Visipaque 320, GE Healthcare, Princeton, NJ, USA) administration protocol (100% contrast, 40/60% contrast/ saline, and 100% saline) was used for retrospective ECG-gated image acquisition (tube current ¼ 400 -800 mA; tube voltage ¼ 100 or 120 kV, gantry rotation 350 ms) using the 64-slice GE Volume CT (GE Healthcare, Waukesha, WI, USA). 10, 14 ECG-based tube current modulation was used in all cases.
CT image analysis
The CT datasets were reconstructed into 10 cardiac phases (5 -95% of the R -R interval) with 1.25-mm slice collimation with an increment of 0.625 mm. This reconstructed slice thickness was selected due to clinical software limitations at the time. Reconstructed ECG-gated CT images were post-processed using the Aquarius iNtuitionWorkstation (TeraRecon, Inc., San Mateo, CA, USA) and interpreted by a single observer. LV function and mass were evaluated at end-systole, enddiastole (both visually determined as the smallest and largest LV sizes, respectively), and at mid-diastole (75%) phases. The cardiac structures and boundaries of the LV cavity and myocardium were identified by the automated software and were manually adjusted to ensure accurate definition of the epicardial and endocardial contours and the mitral valve annular plane. Papillary muscles were not included in the calculation of LV mass ( Figure 1) . for men and women, respectively. 16 We also evaluated LV mass normalized to patient weight [LVMI Weight (g/kg)] and LVEF as alternative prognosticators in this cohort. Optimal thresholds in males, females, and combined were determined using receiver-operator characteristics (ROCs) to form the prognostication model. LVH Weight and LVH BSA prognostic values were evaluated and compared.
Outcome measures
The primary outcome of MACE was a composite of cardiac death, nonfatal MI, and stroke. The secondary outcome was all-cause mortality. Non-fatal MI was defined as myocardial ischaemia and abnormal cardiac biomarkers (.99th percentile of the upper limits of normal). 17 
Statistical analysis
Continuous variables are presented as mean + standard deviation, and categorical variables are presented as frequencies. Student's t-test was used to compare continuous variables and the two-proportion z-test to compare categorical variables. The Pearson correlation coefficient (r) and the Bland -Altman analysis derived reproducibility coefficient (RPC ¼ 1.96 × standard deviation) were used to evaluate agreement between repeat measurements. RPC values represent the 95% confidence interval of agreement assuming Gaussian distribution. The Bland -Altman analysis was also used to determine biases between repeat measurements. ROCs were used to derive optimal LV mass thresholds for classification of non-event vs. event populations. Survival analysis was then performed using the Kaplan -Meier curves using these thresholds, and using the Cox hazard ratio (HR) analysis, with adjustment for the National Cholesterol Education Programme (NCEP) score and history of coronary artery disease (CAD). Log-rank testing was used to determine significant differences in hazards between populations. Statistical significance was defined as P , 0.05. All analyses were performed in Matlab 2013a (Mathworks, Natick, MA, USA). Figure 1 Example trace of the LV myocardium using a mid-diastole (75% phase) contrast-enhanced CT angiography study.
Results
The study cohort was comprised of 166 patients (mean age ¼ 65.7 + 9.7 years, 39% women); of whom, 83 had adverse events (MACE or all-cause mortality) ( Table 1 ). The populations were matched for age, gender, body size, and Morise risk score. Nevertheless, the proportion of smokers and patients with a history of CAD did significantly differ between event and event-free cohorts; and therefore, the average number of risk factors and proportions of mid-and high-risk NCEP groups did as well. These differences were adjusted for in the Cox regression model.
Mean patient heart rates at image acquisition were 53.0 + 7.6 [37-88] bpm and did not differ between cohorts (P ¼ 0.06). Doselength product was 1297 + 391 mGy cm without significant difference between cohorts (P ¼ 0.9).
Phase variability
There was high correlation of LV mass measures between the three cardiac phases ( Figure 2 ). The Pearson r correlation between phases was .0.945. The Bland -Altman plots demonstrated small, but statistically significant (P , 0.001) biases in the measures of enddiastolic LV mass (5.7 and 6.4 g less than mid-and end-diastolic, respectively) ( Figure 2) . Mid-diastolic and end-systolic LV mass measures did not differ significantly (P ¼ 0.4). Nevertheless, biases remained ,4% of average LV mass.
Intra-observer variability
Intra-observer variability results are shown in Figure 3 for middiastole phase. As expected, the Pearson r values were higher, and RPC values were lower than between phases (Figure 2) , which comprise of both inter-phase and intra-observer variabilities. LV mass measures were most reproducible (RPC ¼ 25 g and 14% of mean LV mass values) at mid-diastole (P , 0.01) compared with 31 and 37 g at end-systole and end-diastole, respectively. Respective Pearson r values were 0.981, 0.971, and 0.955.
Cardiac events
At follow-up, all-cause mortality was observed in 48 patients (28.9%), cardiac death in 17 patients, non-fatal MI in 34 patients, and stroke in 1 patient (Table 1) . Additionally, 53 patients underwent revascularization (40 percutaneous coronary interventions and 13 bypass surgeries). Eight patients had valve surgery, but these were evenly split between the cohorts. Of the non-cardiac deaths, 16 were attributed to cancer, 3 intra/post-cardiac operation, 2 sepsis, 1 pulmonary artery hypertension, 1 unknown, and 8 from other causes.
We observed that mean mid-diastole LV mass tended to be higher (P ¼ 0.06) in patients with events than in those without events ( Table 2) . However, LVMI differences between these same cohorts reached higher statistical significance, as did LV mass/weight (P , 0.01).
Using ROC analysis (Figure 4) , optimal cut-points were derived for LVMI BSA and LVMI Weight in males and females combined and separately ( Table 3) . ROC area under the curve (AUC) indicated reduced ability to prognosticate males compared with females. ROC analysis derived LVMI BSA cut-points for males and females in this cohort were similar (difference ,15%) to those determined by Mao et al. 16 Therefore, in all subsequent analyses, LVH BSA was determined using the thresholds defined by Mao et al. ( Table 4 ), but unadjusted LV mass was not (data not shown). The prognostic power of LV mass metrics was greater than that of NCEP alone as demonstrated by ROC curves and AUC (Figure 4 ), but only reached significance with LVMI Weight (P , 0.05). Combined prognostic models, incorporating NCEP, did not increased ROC AUC significantly (P . 0.3). NCEP and history of CAD adjusted HRs from the Cox proportional hazard regression are listed in Table 5 for both the continuous variable and the discrete cut-point comparison using both a single and separate cut-points for each sex. All metrics were independent predictors of MACE and all-cause death independent of NCEP and previous history of CAD (P , 0.05). LVMI Weight appeared to have better prognostic value compared with the LVMI BSA and LVEF as indicated by higher discrete HR and smaller P-values.
Discussion
Our study results demonstrate that LV mass measurements are consistent across different cardiac phases with the Pearson correlation coefficients .0.94 and biases ,4% and that LV mass measures from the mid-diastolic phase had prognostic value for MACE and all-cause death. Thus, important prognostic value may be derived from anatomical cardiac CT scans with either retrospective or prospective ECG gating.
Measurements of LV mass
Traditionally, LV mass is most commonly measured with echocardiography using measurements obtained in a single view using geometrical assumptions. 5 This method is prone to significant error, especially when hypertrophy is eccentric or asymmetric. Conversely, cardiac CT is a three-dimensional modality that permits the accurate assessment of volumes. However, as a radiation reduction technique, images are acquired prospectively; thus, acquisition can only be performed in mid-diastole when cardiac motion is minimal. 8 Therefore, our ability to translate measures of LV mass at this portion of the cardiac cycle must be demonstrated. Our results demonstrate that LV mass measures at mid-diastole are similar to those acquired at end-diastole with no significant bias. Inter-phase variability of LV mass measurement (RPC) was ,41 g. Accounting for the 25 g intra-observer variability we measured in this study, ,35 g variability can be attributed to inter-phase differences alone (corresponding to coefficient of variation ,10%). A previous study by Budoff et al. found there was high correlation (Pearson r ¼ 0.96) between observers and between cardiac phases (r ¼ 0.98), which were similar to our own results. Likewise, Budoff et al. reported ,6.2% bias (a difference of 3.7 g/m 2 ) between LV mass/BSA measured in end-diastole and end-systole with 64-slice CT, 9 which are consistent with our measurements. The bias between our end-diastolic and end-systolic measures was 3.7 g/m 2 , and the bias between our end-diastolic and mid-diastolic measures was 2.8 g/m 2 . Our results suggest that mid-diastolic LV mass values were more reproducible (intra-observer RPC ¼ 25 g) than at either enddiastole or end-systole (37 or 31 g, respectively) ( Figure 2) , which is likely associated with reduced wall motion at this phase and better edge definition. Furthermore, we did not detect significant phase-related differences in the prognostic power of LVMI BSA and LVMI Weight . Thus, prospectively gated mid-diastolic cardiac CT is advantageous for its lower radiation dose while maintaining its prognostic value for MACE and all-cause death.
Prognostic value of LV mass
De Simone et al. found that the hazard of heart failure increased by 3% for each 1 g/m 2 increase in echocardiographic LV mass index. 18 Our Cox regression results demonstrate a more modest, 1% increase of MACE or all-cause death for each 1 g/m 2 increase of LVMI BSA . In general, previous studies reported that echocardiographic LVH was associated with higher CV morbidity, in patients with hypertension. 1 Studies have demonstrated that a reduction in LV mass with antihypertensive drugs could reduce the CV morbidity and mortality. 4, 19 Therefore, the accurate assessment of LV mass may lead to earlier identification and treatment. Mid-diastole LV mass was greater in the events group than the event-free group, as were LVMI BSA and LVMI Weight ( Table 2) . Furthermore, ROC curve analysis demonstrates that LVH BSA as previously defined by Mao et al. 16 and measured at mid-diastole LVMI BSA predicted MACE and all-cause death ( Table 5) . Optimal LVMI BSA cutpoints, derived using ROC analysis, did not significantly differ from those previously defined by Mao et al.-corroborating their findings. As part of this work, we also explored other LV mass measures as prognosticators. We found that in this dataset, LVMI Weight (g/kg) had significantly higher prognostic value than LVMI BSA (Cox hazards ratios 2.47 and 1.85, respectively). While reporting LVMI BSA is clinical routine, these preliminary results may indicate that LVMI Weight may better stratify patients at elevated risk of MACE. Nevertheless, these findings need to be confirmed in a separate and larger patient cohort before they can be applied clinically.
LVEF also had prognostic value in this cohort, but it requires retrospective ECG-gated image acquisition which is associated with greater radiation exposure to the patient. LVEF HRs did not exceed those LVMI Weight and are thus considered to have inferior prognostic value for MACE and all-cause death. However, it is worth Prognosis of LV mass stating that LVEF , 35% is used for prognosticating adverse events in the context of heart failure. The ROC-derived thresholds for LVEF in this work were much higher ( 62%). These high thresholds are in part due to the patient cohort, with only 17 (10%) patients having LVEF , 35%.
Clinical implications
Magnetic resonance (MR) imaging is an established gold standard for LV and RV mass and volume measurement and does not entail the use of ionizing radiation nor contrast. Nevertheless, the CT-derived LV mass measurement remains useful in patients with contraindications to MR (e.g. claustrophobia implanted devices) and in patients referred to cardiac CT for other indications such as evaluation of the coronary arteries.
As with other imaging modalities, segmentation of the LV myocardium was a semi-automated procedure which can be time consuming. Therefore, improved image analysis software that is able to automatically and reliably delineate the myocardial walls and valve planes is desirable to ease workflow.
Study limitations
This is a single-centre study with a relatively small sample size and a small number of outcomes. Despite this, previous studies have used smaller sample sizes (38 -104 patients) . 4, 20 The similarity of our Prognosis of LV mass degrees of variability in LVMI estimates with past studies 9 and the strong correlations suggests that our results are robust. The true prognostic value of LVH may be underestimated, since LVH has been associated with diastolic dysfunction and congestive heart failure and these were not collected. 21 Future prospective studies are needed to confirm our results in an independent population, and determine prognostic value for other outcomes and impact of therapy on these outcomes.
Conclusions
LV mass measurements in mid-diastole, end-diastole, and endsystole are highly correlated, with mid-diastole having the best intra-observer reproducibility. LV mass calculated using middiastolic images has prognostic value of adverse events, and incremental prognostic value over NCEP risk.
